255 related articles for article (PubMed ID: 22013521)
1. Symptomatic therapy and rehabilitation in primary progressive multiple sclerosis.
Khan F; Amatya B; Turner-Stokes L
Neurol Res Int; 2011; 2011():740505. PubMed ID: 22013521
[TBL] [Abstract][Full Text] [Related]
2. Societal costs of primary progressive multiple sclerosis in Australia and the economic impact of a hypothetical disease-modifying treatment that could delay disease progression.
Brown LJ; Li J; Brunner M; Snoke M; La HA
J Med Econ; 2021; 24(1):140-149. PubMed ID: 33461357
[TBL] [Abstract][Full Text] [Related]
3. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
4. Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A; Thanei GA; Harp C; Bernasconi C; Bonati U; Cross AH; Fischer S; Gaetano L; Hauser SL; Hendricks R; Kappos L; Kuhle J; Leppert D; Model F; Sauter A; Koendgen H; Jia X; Herman AE
EBioMedicine; 2023 Jul; 93():104662. PubMed ID: 37354600
[TBL] [Abstract][Full Text] [Related]
5. Genetic differences between primary progressive and relapsing-remitting multiple sclerosis: The impact of immune-related genes variability.
Kiselev I; Bashinskaya V; Baulina N; Kozin M; Popova E; Boyko A; Favorova O; Kulakova O
Mult Scler Relat Disord; 2019 Apr; 29():130-136. PubMed ID: 30711878
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study.
Pöhlau D; Przuntek H; Sailer M; Bethke F; Koehler J; König N; Heesen C; Späth P; Andresen I
Mult Scler; 2007 Nov; 13(9):1107-17. PubMed ID: 17623736
[TBL] [Abstract][Full Text] [Related]
7. Ocrelizumab: A Review in Multiple Sclerosis.
Lamb YN
Drugs; 2022 Feb; 82(3):323-334. PubMed ID: 35192158
[TBL] [Abstract][Full Text] [Related]
8. Genetics of primary progressive multiple sclerosis.
Cree BA
Handb Clin Neurol; 2014; 122():211-30. PubMed ID: 24507520
[TBL] [Abstract][Full Text] [Related]
9. CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
Iwanowski P; Losy J; Kramer L; Wójcicka M; Kaufman E
J Neurol Sci; 2017 Sep; 380():22-26. PubMed ID: 28870573
[TBL] [Abstract][Full Text] [Related]
10. Employment and absenteeism in working-age persons with multiple sclerosis.
Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
[TBL] [Abstract][Full Text] [Related]
11. Disease-Modifying Treatment in Progressive Multiple Sclerosis.
Ciotti JR; Cross AH
Curr Treat Options Neurol; 2018 Apr; 20(5):12. PubMed ID: 29627873
[TBL] [Abstract][Full Text] [Related]
12. Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome.
Kantarci OH; Lebrun C; Siva A; Keegan MB; Azevedo CJ; Inglese M; Tintoré M; Newton BD; Durand-Dubief F; Amato MP; De Stefano N; Sormani MP; Pelletier D; Okuda DT
Ann Neurol; 2016 Feb; 79(2):288-94. PubMed ID: 26599831
[TBL] [Abstract][Full Text] [Related]
13. Natural history of primary progressive multiple sclerosis.
Ebers GC
Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
[TBL] [Abstract][Full Text] [Related]
14. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
15. Palliative care interventions for people with multiple sclerosis.
Latorraca CO; Martimbianco ALC; Pachito DV; Torloni MR; Pacheco RL; Pereira JG; Riera R
Cochrane Database Syst Rev; 2019 Oct; 10(10):CD012936. PubMed ID: 31637711
[TBL] [Abstract][Full Text] [Related]
16. Genome sequencing uncovers phenocopies in primary progressive multiple sclerosis.
Jia X; Madireddy L; Caillier S; Santaniello A; Esposito F; Comi G; Stuve O; Zhou Y; Taylor B; Kilpatrick T; Martinelli-Boneschi F; Cree BAC; Oksenberg JR; Hauser SL; Baranzini SE
Ann Neurol; 2018 Jul; 84(1):51-63. PubMed ID: 29908077
[TBL] [Abstract][Full Text] [Related]
17. Multiple sclerosis by phenotype in Germany.
Engelhard J; Oleske DM; Schmitting S; Wells KE; Talapala S; Barbato LM
Mult Scler Relat Disord; 2022 Jan; 57():103326. PubMed ID: 35158442
[TBL] [Abstract][Full Text] [Related]
18. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis.
Bieniek M; Altmann DR; Davies GR; Ingle GT; Rashid W; Sastre-Garriga J; Thompson AJ; Miller DH
J Neurol Neurosurg Psychiatry; 2006 Sep; 77(9):1036-9. PubMed ID: 16793860
[TBL] [Abstract][Full Text] [Related]
19. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
[TBL] [Abstract][Full Text] [Related]
20. A patient with established primary progressive multiple sclerosis transitions to 'secondary' relapsing-remitting disease course following a fulminant demyelinating episode.
Tutuncu M; Demirci NO; Özer F; Saip S; Kantarci OH; Siva A
Mult Scler; 2011 Oct; 17(10):1262-4. PubMed ID: 21135019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
